Nkarta Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.8%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.48next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2K
NKX019 Dose Level (Cells per Cycle) Quarterly12B
Watch Items
- Initial clinical data presentation from Ntrust-1 and Ntrust-2 trialsTrigger: Presentation of meaningful clinical data set at a medical conference in 2026Action: Evaluate depth and durability of B-cell depletion and clinical response to validate therapeutic efficacy
- Outpatient dosing expansion in community-based settingsTrigger: FDA agreement and IRB approvals of protocol amendmentsAction: Monitor patient enrollment rates and reduction in patient burden across community rheumatology centers
Research as of 19 Jun 2026